Study of Multiple-dose Kukoamine B Mesilate in Healthy Vo... | NCT02690961

NCT02690961

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

ID	Type	Description	Link
ChiCTR-TRC-14005111	Registry Identifier	Chinese Clinical Trial Registry

Status Module

Name	Class
Southwest Hospital, China	OTHER

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Kukoamine B Mesilate 0.06mg/kg	Experimental	Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Drug: Kukoamine B Mesilate
Kukoamine B Mesilate 0.12mg/kg	Experimental	Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Drug: Kukoamine B Mesilate
Kukoamine B Mesilate 0.24mg/kg	Experimental	Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Drug: Kukoamine B Mesilate
Placebo 0.06mg/kg	Experimental	Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Drug: placebo multiple doses
Placebo 0.12mg/kg	Experimental	Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Drug: placebo multiple doses

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Kukoamine B Mesilate	Drug	Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.	Kukoamine B Mesilate 0.06mg/kg Kukoamine B Mesilate 0.12mg/kg

Outcomes Module

Measure	Description	Time Frame
Incidence of adverse events.	adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).	14 days

Secondary Outcomes

Measure	Description	Time Frame
Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])	before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.	the first day,the sixth day(before the three injections from bottom),the seventh day

Other Outcomes

Measure	Description	Time Frame
Pharmacokinetic parameters(Area Under Curve [AUC])	before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.	the first day,the sixth day(before the three injections from bottom),the seventh day

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Gender: male or female, each sex ratio does not exceed 2/3;
18-45 years (including upper and lower limit), the general situation is good;
Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.

Exclusion Criteria:

Primary disease in important organs;
Mental or physical disability;
Familial hereditary disease;
Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
History of immunodeficiency diseases, including HIV antibody positive;
Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
Alcohol and drug abusers;
Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form（CRF）;
The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
Lactating women, pregnant women or unable to take effective contraceptive measures;
Researchers believe that participants not suitable to take the test for other factors .